Quick Facts

• Relieves Symptoms: Nausea and vomiting.
• Patient Population: Adults and adolescents (aged 12 years and older and weighing at least 35 kg).

---

Cinet: Main Uses and Benefits

Cinet is a medication utilized to provide relief from the symptoms of nausea (feeling sick) and vomiting (being sick). Its primary use is in the management of these specific conditions in adults and in adolescents aged 12 years and older who weigh 35 kg or more.

The active substance in Cinet is domperidone, which functions to increase the movements or contractions of the stomach and upper intestines. This prokinetic action facilitates the movement of food through the digestive tract, which helps to alleviate the feelings of nausea and the act of vomiting.

Treatment with Cinet is typically for a short duration, as symptoms often subside within a few days. The medication should be used at the lowest effective dose for the shortest time necessary to control symptoms. Patients should not take this medication for longer than one week without consultation from a healthcare professional.

The benefits of Cinet are tied to its ability to address and relieve the symptoms of nausea and vomiting, restoring comfort to the patient during acute episodes.

Eligibility Scope

The officially approved population for Cinet includes adults and adolescents aged 12 years and older weighing at least 35 kg. Use is not recommended in children under 12 or in adolescents weighing less than 35 kg, as efficacy in these groups is not established according to regulatory sources.

Contraindicated Populations

Cinet is contraindicated by regulatory labels in several groups, primarily due to cardiac risk:

• Patients with moderate or severe hepatic impairment.
• Patients with pre-existing QTc prolongation, significant electrolyte disturbances, or underlying cardiac diseases such as congestive heart failure.
• Patients concurrently taking QT-prolonging medicines or potent CYP3A4 inhibitors.
• The medicine is also forbidden in patients with a prolactinoma or when stimulating gastrointestinal motility could be harmful (e.g., in cases of hemorrhage or obstruction).

Eligibility-Related Restrictions

Older adults (over 60 years) should use Cinet with caution due to a higher observed cardiac risk. Patients with severe renal impairment require restricted use where dosing frequency must be reduced. The medicine is not recommended for breastfeeding mothers, and use during pregnancy is permitted only when justified by the anticipated therapeutic benefit.

Cinet (domperidone) can interact with a wide range of medicines and products, which can increase the risk of serious side effects, particularly affecting the heart rhythm. It is essential to inform your doctor or pharmacist of all medicines you are taking, including over-the-counter drugs, vitamins, and herbal supplements.

Contraindicated Drug Combinations (Avoid)

Cinet should not be taken with medicines that can significantly slow down the heart or prolong the QT interval on an electrocardiogram (ECG), as this raises the risk of life-threatening cardiac rhythm disorders (e.g., Torsades de Pointes). Examples of medicines to avoid include:

• Certain Antifungals: Specific oral azole antifungals, such as ketoconazole, fluconazole, or voriconazole.
• Certain Antibiotics: Macrolide antibiotics, such as erythromycin or clarithromycin.
• Certain Heart and Blood Pressure Medications: Amiodarone or dronedarone.
• Other Agents: Apomorphine, which requires close monitoring if co-administered.

Other Important Interactions

Type of Interaction	Effect/Warning	Examples of Interacting Products
CNS Depressants	Increased drowsiness or sedation.	Alcohol, opioids, sedatives, tranquilizers.
Anticholinergics	Reduced Cinet effectiveness; increased risk of side effects like dry mouth, constipation, and urinary retention.	Antispasmodics, some antihistamines (e.g., diphenhydramine).
CYP3A4 Inhibitors	Increased Cinet blood levels, raising the risk of toxicity.	Certain HIV protease inhibitors, some calcium channel blockers.

Inform your healthcare provider if you are taking any of these products. They may need to adjust your dose or monitor you closely.

Cinet is a specific, small-molecule inhibitor that selectively targets the A1α receptor located on the surface of osteoclast precursor cells and mature osteoclasts. This direct molecular binding initiates the drug's mechanism.

Upon binding, Cinet acts as a non-competitive antagonist, impeding the ability of RANKL to signal through the A1alpha receptor. This targeted receptor interaction disrupts the NF-kappa B and MAPK intracellular signaling cascades. These cascades are essential for the processes of osteoclast differentiation, maturation, and survival.

This pathway modulation results in a reduction of osteoclastogenesis (the formation of new osteoclasts) and a decrease in the overall activity of existing bone-resorbing osteoclasts. The resulting decrease in bone resorption activity is the primary system-level physiological consequence of Cinet's action, shifting the net balance of bone remodeling toward formation.

How to use Cinet: Administration Guidelines

Cinet (Domperidone) is administered via the oral or rectal route, depending on the dosage form available, such as tablets, oral suspension, or suppositories. Usage involves following the lowest effective dose for the shortest possible duration.

Labeled Dosing and Schedule

Patient Group	Single Dose	Maximum Daily Dose	Frequency	Duration
Adults and Adolescents (≥ 12 years and ≥ 35 kg)	10 mg (tablet or suspension)	30 mg	Up to three times per day	Typically no longer than 7 days
Suppository (Adults)	30 mg	60 mg	Up to two times per day	Typically no longer than 7 days

Administration Conditions

• Timing: Oral forms of Cinet should be taken before meals (e.g., 15 to 30 minutes prior) to avoid delayed absorption of the active substance.
• Preparation: Oral suspensions must be shaken before each use. Standard tablets must be swallowed whole with water and must not be crushed or chewed.
• Missed Dose: If a dose is missed, it should be omitted, and the patient should resume the regular dosing schedule. The dose must not be doubled to compensate for a forgotten dose.
• Special Population: For patients with severe renal impairment, the dosing frequency is reduced to once or twice daily, depending on the severity of the condition, and the dose may require reduction.

Research evidence / Overview of studies for Cinet

Evidence for Symptomatic Relief of Nausea and Vomiting

The primary research for CINET (Domperidone) has focused on trials that evaluated short-term symptom patterns related to feeling sick (nausea) and being sick (vomiting). The most common type of research used in research exploring how symptoms change over time involves short-term Randomized Controlled Trials (RCTs). These studies often compare the medicine's effect to that of a placebo (an inactive substance) or sometimes to other treatments.

In these trials, studies monitored several outcomes related to physical discomfort, such as the frequency of vomiting and nausea scores. Research reports changes measured during the study period, which often lasted for only a few days to a week, reflection of the short time intervals studied in the research. The findings contribute to the broader body of research describing symptom patterns in people experiencing these acute episodes.

Study Focus on Associated Digestive Symptoms

In addition to the feeling of sickness, studies examined whether CINET was associated with changes in other symptoms conditions marked by functional limitations in the upper digestive tract. These outcomes related to physical discomfort include feelings of epigastric fullness (a heavy feeling in the upper stomach) and abdominal distension (bloating).

Research has explored how these symptoms were observed to evolve in the study populations. The findings describe patterns observed in the studies related to these specific physical sensations. However, the overall body of research remains limited regarding long-term chronic digestive conditions like functional dyspepsia.

Evidence in Specific Patient Populations

The main clinical research was evaluated in adults and adolescents who are 12 years and older and weigh at least 35 kg. The results apply only to the populations studied—meaning the observed patterns should be considered only for these groups.

Research was observed in some studies involving children younger than 12 years, but these studies were limited and did not report a consistent difference in outcomes when compared to a placebo. Because of this, the data for certain groups remain insufficient to support the medicine's use in younger children, and regulatory bodies have restricted the authorized population.

Duration of Treatment and Long-Term Follow-up

Research focused on episodes where symptoms become more noticeable, and consequently, the follow-up durations were limited. Most of the clinical data comes from trials that lasted for only a very short time, typically one week or less, which aligns with the defined time intervals studied in the research for acute symptom patterns. This limited information for long-term outcomes is consistent with the regulatory decision to limit the authorized use to short-term symptom measurement.

Research Gaps and Areas of Regulatory Uncertainty

A key element of the scientific review is understanding where the evidence has gaps. For example, while the medicine was studied for chronic conditions like dyspepsia (long-lasting indigestion) and gastro-oesophageal reflux in the past, regulators determined that the body of research was insufficient to continue supporting these uses.

Additionally, the evidence quality varies across studies, and some research is limited by modest sample sizes. The comparative evidence is lacking in some contexts, making it harder to contextualize the findings against other available treatments. These limitations in the research indicate what is still uncertain about the medicine beyond its authorized, short-term role.

Common questions about Cinet (FAQ)

---

Q: How long does it take for Cinet to start working?

A: Official documents containing information about Cinet's action describe the active substance as being rapidly absorbed following oral use. Studies indicate that the concentration of the medicine peaks in the bloodstream at approximately one hour after it is administered.

Q: Are there any major food restrictions while using Cinet?

A: Regulatory sources generally do not list major, specific food restrictions that must be avoided while using Cinet. The primary guidance is related to the timing of use; official information recommends that oral forms of the medicine be taken before meals.

Q: Can Cinet be taken with common pain relievers like ibuprofen?

A: The official interaction lists focus on avoiding medicines that slow the heart rhythm (QT-prolongers) or drugs that significantly alter Cinet's metabolism. Common non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, are typically not listed among the specifically contraindicated medications in these documents. Questions regarding specific combinations of medicines are typically directed to a healthcare provider.

Q: What happens if Cinet is used for a long time?

A: Official regulatory documents explicitly restrict the use of Cinet to the shortest possible duration, typically no longer than one week. Safety documents indicate that prolonged use or high doses have been associated with an observed increased risk of serious ventricular arrhythmias and sudden cardiac death.

Q: What is the procedure for a missed dose of Cinet?

A: If a dose of Cinet is forgotten, official guidance is to simply omit that missed use and resume the normal dosing schedule. Regulatory guidance indicates that the dose is not to be doubled to compensate for the forgotten one.

Q: Is it necessary to avoid alcohol completely while using Cinet?

A: Alcohol is categorized as a Central Nervous System (CNS) depressant. Combining CNS depressants with Cinet may increase the likelihood of certain side effects, such as drowsiness. The combination is noted to carry an observed risk of increased side effects, leading regulatory sources to advise against co-use.

Q: Does Cinet affect my sleep?

A: Official safety documents include sleep-related effects, such as sleepiness (somnolence) and insomnia, in the list of rare or very rare reported adverse reactions. Additionally, agitation and nervousness are also noted as very rare effects, which could indirectly affect sleep patterns.

Q: Is it normal to feel a little dizzy when starting Cinet?

A: Dizziness has been documented in official safety information as a very rare adverse reaction. While the occurrence is infrequent, patients experiencing this or any unexpected symptom are advised to discuss it with their healthcare professional.

Q: Can Cinet cause changes in mood or anxiety?

A: Official safety data lists certain psychiatric effects. Depression has been cited as a common adverse reaction in some clinical trials. Furthermore, agitation and nervousness are noted as very rare psychiatric disorders in regulatory documents.

Q: What has the research evidence shown regarding Cinet's long-term safety?

A: The majority of clinical research supporting Cinet's use is derived from short-term trials lasting one week or less. The documented safety concerns regarding the observed increased risk of serious heart rhythm problems and sudden cardiac death served as the basis for regulatory bodies to restrict the authorized dose and duration of use.

Q: Can Cinet affect the results of lab tests?

A: Official safety information notes that Cinet can be associated with certain changes in laboratory measurements. Specifically, it can lead to abnormal liver function tests and elevated levels of prolactin in the blood. It is also known to increase the QTc interval, which is monitored on an electrocardiogram (ECG).

Q: Is Cinet considered a high-risk medication?

A: Cinet is generally available by prescription only and is associated with important safety considerations, particularly a small increased risk of serious heart rhythm disorders. This led regulatory agencies to implement specific restrictions regarding its dose, duration, and patient eligibility, demonstrating the importance of medical supervision during its use.

Q: Does Cinet have a specific time of day it should be used?

A: Official guidance emphasizes that oral forms of Cinet should be taken before meals (for example, 15 to 30 minutes prior). Depending on the dosing schedule provided by a healthcare professional, some official sources advise that it may also be used at bedtime if required.

Q: Are there different strengths of Cinet available?

A: Official product information shows that Cinet is available in several pharmaceutical preparations. These include a 10 mg oral tablet, oral suspension (often 1 mg/mL), and a 30 mg suppository, though the availability of specific forms depends on the region.

Q: How is Cinet eliminated from the body?

A: Regulatory documents describe Cinet as being extensively metabolized in the liver before it is removed from the body. Official data indicates that the medicine is primarily eliminated through the feces (approximately 66% of a dose) and via the urine (approximately 31% of a dose).

Q: Can I drive or operate machinery while using Cinet?

A: Official labeling advises that side effects such as sleepiness, dizziness, or rare neurological effects can occur with Cinet. Official labeling advises that if affected by these symptoms, the person's ability to drive or operate machinery may be impaired.

Q: Does Cinet need any special monitoring or blood tests?

A: Official safety warnings indicate the importance of monitoring for signs of heart rhythm disorders. Before and during treatment, official guidelines suggest that electrolyte levels, such as potassium, should be corrected and monitored due to their influence on cardiac risk. The medicine is also known to increase prolactin levels.

Q: What evidence exists for Cinet's use in combination with other treatments?

A: Published research has explored Cinet in combination with certain other medicines. This includes its use in combination with acid-reducing medicines (such as Proton Pump Inhibitors) for digestive conditions, and also with pain relievers for overall symptom relief.

Q: How does Cinet's action compare to placebo in clinical trials?

A: Regulatory reviews of clinical trials generally describe that Cinet was associated with a statistically greater change in measured symptoms compared to a placebo. This finding primarily relates to the short-term relief of nausea and vomiting during the study periods.

How to Store and Dispose of Cinet

Cinet (Domperidone) must be stored at room temperature, which regulatory documents define as not exceeding 25 C. The medicine must be kept in a cool, dry place, protected from excessive heat, moisture, and direct sunlight. To maintain product integrity, keep Cinet in its original container and ensure the container is tightly closed; tablets should remain in their blister pack until use. As a mandatory safety requirement, Cinet must be stored out of the reach and sight of children.

Expired or unused Cinet should not be kept. The official disposal protocol requires the product to be returned to a pharmacist through a drug take-back program. It must not be released into the environment, such as by disposing of it in household trash or emptying it into drains.